Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 543 Triple Negative Breast Neoplasms 97 Ovarian Neoplasms 58 Colorectal Neoplasms 50 Prostatic Neoplasms 46 Carcinoma, Non-Small-Cell Lung 44 Neoplasms 38 Lung Neoplasms 33 Melanoma 29 Endometrial Neoplasms 29 Neoplasm Metastasis 28 Stomach Neoplasms 26 Pancreatic Neoplasms 26 Uterine Cervical Neoplasms 25 Squamous Cell Carcinoma of Head and Neck 22 Colonic Neoplasms 20 Head and Neck Neoplasms 18 Carcinoma, Renal Cell 18 Esophageal Neoplasms 16 Sarcoma 14 Advanced Breast Cancer 14 Small Cell Lung Carcinoma 13 Urinary Bladder Neoplasms 12 Liver Neoplasms 11 Carcinoma, Transitional Cell 11 Kidney Neoplasms 10 Carcinoma, Intraductal, Noninfiltrating 10 Brain Neoplasms 10 Lymphedema 9 Anatomic Stage I Breast Cancer AJCC v8 9

Interventions

Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Breast × 30 days × Clear all

NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡